An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks (Q3W) in Japanese Subjects With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2017
At a glance
- Drugs Anetumab ravtansine (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Bayer
- 27 Jul 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2017 Planned End Date changed from 11 May 2018 to 31 Aug 2017.
- 04 May 2017 Status changed from recruiting to active, no longer recruiting.